Nurse Loses Drug-Prescribing Rights in Swift DEA Revocation
Published Date: 2/21/2025
Notice
Summary
Jason Weakley, a nurse practitioner, lost his DEA registrations for Vermont and New Hampshire because he no longer has permission to handle controlled substances in those states. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his certificates. This means he can’t legally prescribe or manage controlled drugs in these states anymore, effective immediately.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registrations Revoked; Renewals Denied
The DEA revoked Jason Weakley’s Certificates of Registration Nos. MW7073757 (Vermont) and MW7551460 (New Hampshire), so he cannot legally prescribe, dispense, or handle controlled substances in Vermont or New Hampshire. The Order also denies any pending applications to renew, modify, or obtain additional registration in those two states. The Order is effective March 24, 2025; the record shows his Vermont RN and APRN licenses were expired and suspended as of January 15, 2024, and his New Hampshire RN and APRN licenses expired March 23, 2024.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
2026-13580 — Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
2026-13364 — Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
Starting July 1, 2026, the DEA is temporarily putting four new substances—5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move helps keep these potentially dangerous drugs off the streets while the DEA studies them further.
Previous / Next Documents
Previous: 2025-02935 — Combined Notice of Filings
The Federal Energy Regulatory Commission got new requests from natural gas companies to change pipeline rates and agreements starting as soon as February 1, 2025. These changes could affect how much customers pay or get refunded. If you want to speak up or get involved, you need to act by the listed deadlines in February and March.
Next: 2025-03023 — Sunshine Act Meetings
The National Council on Disability is holding a two-day meeting on March 6-7, 2025, both in Washington, DC, and online. They’ll discuss important topics like tax issues for disabled workers, disaster experiences, and ethics training, with a special chance for the public to share their thoughts. This meeting affects people with disabilities, advocates, and anyone interested in disability rights, with no new costs but plenty of fresh ideas and updates.